Maribel Casas

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

Miguel Martín, Jan C. Brase, Lourdes Calvo et al. · Breast Cancer Research · 2014 · 164 citations · Full text

Medicine, Endocrinology, Oncology +16

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

Miguel Martín, Aleix Prat, Álvaro Rodríguez-Lescure et al. · Breast Cancer Research and Treatment · 2013 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study

Miguel Martín, Amparo Ruiz Simón, Manuel Ruíz Borrego et al. · Journal of Clinical Oncology · 2015 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

Emilio Alba, Aňa Lluch, Nuria Ribelles et al. · The Oncologist · 2016 · 58 citations · Full text

Medicine, Cancer Biology, Oncology +17

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

Miguel Martín, Jan C. Brase, Aleix Prat et al. · Breast Cancer Research and Treatment · 2016 · 54 citations · Full text

Medicine, Gynecology, Oncology +16